AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term, we believe ...
Ubisoft's capital structure in on the weaker side for a video game publisher that has to deal with swings in revenue while investing in content development. The firm generated EUR 310 million in free ...